<ul>
<li>3 只医疗保健股票将受益于这项伟大的美好法案</li>
</ul>
<p>Humana Inc.（纽约证券交易所代码：HUM - 免费报告）- Zacks Research 的股票分析师在 5 月 13 日星期三发布的研究报告中下调了对 Humana 2027 年第一季度每股收益（EPS）的预期。Zacks Research 分析师团队现在预计该保险提供商在本季度将每股盈利 8.69 美元，低于之前预测的 8.98 美元。Zacks Research 对该股票给予了 “强烈卖出” 的评级。市场普遍预计 Humana 当前全年的每股收益为 9.06 美元。Zacks Research 还对 Humana 2027 财年的每股收益预期为 13.26 美元。</p>
<p>HUM 还受到其他多份报告的关注。巴克莱将 Humana 的目标股价从 176.00 美元上调至 180.00 美元，并在 4 月 30 日星期四的研究报告中给予该股票 “等权重” 评级。富国银行将 Humana 的目标股价从 206.00 美元上调至 227.00 美元，并在 4 月 7 日星期二的报告中给予该公司 “等权重” 评级。Weiss Ratings 在 4 月 21 日星期二的研究报告中重申了对 Humana 的 “卖出（d+）” 评级。摩根大通将 Humana 的目标股价从 180.00 美元上调至 214.00 美元，并在 5 月 1 日星期五的研究报告中给予该公司 “中性” 评级。最后，Leerink Partners 将 Humana 的目标股价从 185.00 美元上调至 255.00 美元，并在 4 月 30 日星期四的报告中给予该公司 “市场表现” 评级。七位股票研究分析师对该股票给予了买入评级，十五位给予了持有评级，四位给予了卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “持有”，平均目标价格为 246.83 美元。</p>
<ul>
<li>联合健康集团：从被排斥到买入的最佳时机</li>
</ul>
<p><strong>查看我们关于 Humana 的最新报告</strong></p>
<h2>Humana 股票表现</h2>
<p>Humana 股票在星期四开盘价为 305.08 美元。该公司的流动比率为 1.77，速动比率为 1.77，债务与股本比率为 0.66。该股票的 50 日移动平均价格为 200.35 美元，200 日移动平均价格为 226.42 美元。该公司的市值为 366.3 亿美元，市盈率为 32.63，市盈增长比率为 2.73，贝塔值为 0.68。Humana 的 12 个月低点为 163.11 美元，12 个月高点为 315.35 美元。</p>
<ul>
<li>2 只不受关税影响的医疗保健抗衰退股票</li>
</ul>
<p>Humana（纽约证券交易所代码：HUM - 获取免费报告）最近在 4 月 29 日星期三发布了其财报。该保险提供商报告本季度每股收益为 10.31 美元，超出分析师一致预期的 9.97 美元，超出幅度为 0.34 美元。Humana 的股本回报率为 10.45%，净利润率为 0.82%。该公司在本季度的收入为 396.5 亿美元，而分析师预期为 393.7 亿美元。在去年同期，该公司每股收益为 11.58 美元。Humana 的收入同比增长 23.5%。Humana 已将其 2026 财年的指导目标设定为每股收益 9.000。</p>
<h2>Humana 宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 7 月 31 日星期五支付。6 月 26 日星期五的股东将获得每股 0.885 美元的分红。这相当于年化分红为 3.54 美元，分红收益率为 1.2%。除息日为 6 月 26 日星期五。Humana 的分红支付比率（DPR）目前为 37.86%。</p>
<h2>内部交易活动</h2>
<p>在其他 Humana 新闻中，内部人士 Sanjay K. Shetty 在 2 月 23 日星期一购买了 810 股该公司的股票。每股的平均购买成本为 185.21 美元，总交易额为 150,020.10 美元。购买后，该内部人士直接持有该公司 11,657 股股票，价值为 2,158,992.97 美元。这代表了他们持股比例的 7.47% 的增长。该收购已在与 SEC 的法律文件中披露，可以通过此超链接访问。当前，内部人士持有该股票的 0.20%。</p>
<h2>机构投资者对 Humana 的看法</h2>
<p>几家机构投资者最近增加或减少了对 HUM 的持股。资本国际投资者在第四季度将其在 Humana 的持股增加了 113.9%。资本国际投资者现在拥有 5,818,008 股该保险提供商的股票，价值为 14.90239 亿美元，此前在上个季度又增持了 3,097,571 股。马萨诸塞金融服务公司在第三季度将其在 Humana 的持股增加了 273.2%。马萨诸塞金融服务公司现在拥有 3,488,261 股该保险提供商的股票，价值为 9.07541 亿美元，此前在上个季度又增持了 2,553,509 股。挪威银行在第四季度购买了 Humana 的新股份，价值约为 4.56632 亿美元。Pzena 投资管理公司在第一季度将其在 Humana 的持股增加了 34.3%。Pzena 投资管理公司现在拥有 5,470,982 股该保险提供商的股票，价值为 9.48614 亿美元，此前在上个季度又增持了 1,398,774 股。最后，威灵顿管理集团在第四季度将其在 Humana 的持股增加了 4,481.7%。威灵顿管理集团现在拥有 1,196,502 股该保险提供商的股票，价值为 3.06460 亿美元，此前在上个季度又增持了 1,170,387 股。机构投资者和对冲基金持有该公司 92.38% 的股票。</p>
<h2>Humana 公司简介</h2>
<p>（获取免费报告）</p>
<p>Humana Inc（纽约证券交易所代码：HUM）是一家总部位于肯塔基州路易斯维尔的健康保险公司，主要为美国各地的个人和团体提供服务。该公司以其医疗保险业务而闻名，提供医疗保险优势计划和处方药（D 部分）覆盖，同时还提供一系列商业和雇主赞助的团体健康计划。Humana 的产品旨在满足会员的医疗、行为健康和药房需求，特别强调老年人和符合医疗保险资格的人群。</p>
<p>除了传统的保险产品外，Humana 还提供旨在支持慢性病管理、预防护理和护理协调的护理管理和健康服务。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 Humana</li>
<li>保持航班正常的飞机维修公司准备腾飞</li>
<li>Oklo 股票可能准备再次大幅上涨</li>
<li>D-Wave 的财报看起来疲弱，但投资者可能忽视了这一点</li>
<li>随着人工智能反馈循环的加剧，Nebius 的上行空间扩大</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhVTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhVTQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Humana 吗？</h2>
<p>在考虑 Humana 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Humana 并不在名单上。</p>
<p>虽然 Humana 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

休曼纳

医疗业 ETF - Vanguard

医疗业 ETF - SPDR

美国医疗保健供应商 ETF - iShares

标普医疗保健服务 ETF - SPDR

<p>Zacks Research 对 Humana Inc.（纽约证券交易所代码：HUM）发布了负面展望，将其 2027 年第一季度每股收益预期从 8.98 美元下调至 8.69 美元，并维持 “强烈卖出” 评级。全年每股收益的共识预期为 9.06 美元。多位分析师调整了对 Humana 的目标价，平均目标价为 246.83 美元。Humana 的股票开盘价为 305.08 美元，市值为 366.3 亿美元。该公司最近宣布季度股息为 0.885 美元，收益率为 1.2%</p>

<ul>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只医疗保健股票将受益于这项伟大的美好法案</li>
</ul>
</div><p>Humana Inc. (NYSE:HUM - Free Report) - Stock analysts at Zacks Research dropped their Q1 2027 earnings per share (EPS) estimates for Humana in a research note issued on Wednesday, May 13th. Zacks Research analyst Team now anticipates that the insurance provider will earn $8.69 per share for the quarter, down from their previous forecast of $8.98. Zacks Research has a &#34;Strong Sell&#34; rating on the stock. The consensus estimate for Humana's current full-year earnings is $9.06 per share. Zacks Research also issued estimates for Humana's FY2027 earnings at $13.26 EPS.</p>
<div class="lb-trans"><p>Humana Inc.（纽约证券交易所代码：HUM - 免费报告）- Zacks Research 的股票分析师在 5 月 13 日星期三发布的研究报告中下调了对 Humana 2027 年第一季度每股收益（EPS）的预期。Zacks Research 分析师团队现在预计该保险提供商在本季度将每股盈利 8.69 美元，低于之前预测的 8.98 美元。Zacks Research 对该股票给予了 “强烈卖出” 的评级。市场普遍预计 Humana 当前全年的每股收益为 9.06 美元。Zacks Research 还对 Humana 2027 财年的每股收益预期为 13.26 美元。</p>
</div><p>HUM has been the subject of a number of other reports. Barclays upped their price objective on shares of Humana from $176.00 to $180.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Thursday, April 30th. Wells Fargo &amp; Company boosted their price target on shares of Humana from $206.00 to $227.00 and gave the company an &#34;equal weight&#34; rating in a report on Tuesday, April 7th. Weiss Ratings reaffirmed a &#34;sell (d+)&#34; rating on shares of Humana in a research report on Tuesday, April 21st. JPMorgan Chase &amp; Co. increased their price objective on shares of Humana from $180.00 to $214.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, May 1st. Finally, Leerink Partners lifted their price objective on shares of Humana from $185.00 to $255.00 and gave the company a &#34;market perform&#34; rating in a report on Thursday, April 30th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of &#34;Hold&#34; and an average target price of $246.83.</p>
<div class="lb-trans"><p>HUM 还受到其他多份报告的关注。巴克莱将 Humana 的目标股价从 176.00 美元上调至 180.00 美元，并在 4 月 30 日星期四的研究报告中给予该股票 “等权重” 评级。富国银行将 Humana 的目标股价从 206.00 美元上调至 227.00 美元，并在 4 月 7 日星期二的报告中给予该公司 “等权重” 评级。Weiss Ratings 在 4 月 21 日星期二的研究报告中重申了对 Humana 的 “卖出（d+）” 评级。摩根大通将 Humana 的目标股价从 180.00 美元上调至 214.00 美元，并在 5 月 1 日星期五的研究报告中给予该公司 “中性” 评级。最后，Leerink Partners 将 Humana 的目标股价从 185.00 美元上调至 255.00 美元，并在 4 月 30 日星期四的报告中给予该公司 “市场表现” 评级。七位股票研究分析师对该股票给予了买入评级，十五位给予了持有评级，四位给予了卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “持有”，平均目标价格为 246.83 美元。</p>
</div><ul>
<li>UnitedHealth Group: Pariah to Pole Position to Buy the Dip Levels</li>
</ul>
<div class="lb-trans"><ul>
<li>联合健康集团：从被排斥到买入的最佳时机</li>
</ul>
</div><p><strong>Check Out Our Latest Report on Humana</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Humana 的最新报告</strong></p>
</div><h2>Humana Stock Performance</h2>
<div class="lb-trans"><h2>Humana 股票表现</h2>
</div><p>Shares of Humana stock opened at $305.08 on Thursday. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The stock's fifty day moving average price is $200.35 and its 200-day moving average price is $226.42. The firm has a market cap of $36.63 billion, a P/E ratio of 32.63, a P/E/G ratio of 2.73 and a beta of 0.68. Humana has a 12 month low of $163.11 and a 12 month high of $315.35.</p>
<div class="lb-trans"><p>Humana 股票在星期四开盘价为 305.08 美元。该公司的流动比率为 1.77，速动比率为 1.77，债务与股本比率为 0.66。该股票的 50 日移动平均价格为 200.35 美元，200 日移动平均价格为 226.42 美元。该公司的市值为 366.3 亿美元，市盈率为 32.63，市盈增长比率为 2.73，贝塔值为 0.68。Humana 的 12 个月低点为 163.11 美元，12 个月高点为 315.35 美元。</p>
</div><ul>
<li>2 Healthcare Recession-Resistant Stocks Unaffected by Tariffs</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只不受关税影响的医疗保健抗衰退股票</li>
</ul>
</div><p>Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, beating analysts' consensus estimates of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The business had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. During the same period in the previous year, the company posted $11.58 EPS. Humana's revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS.</p>
<div class="lb-trans"><p>Humana（纽约证券交易所代码：HUM - 获取免费报告）最近在 4 月 29 日星期三发布了其财报。该保险提供商报告本季度每股收益为 10.31 美元，超出分析师一致预期的 9.97 美元，超出幅度为 0.34 美元。Humana 的股本回报率为 10.45%，净利润率为 0.82%。该公司在本季度的收入为 396.5 亿美元，而分析师预期为 393.7 亿美元。在去年同期，该公司每股收益为 11.58 美元。Humana 的收入同比增长 23.5%。Humana 已将其 2026 财年的指导目标设定为每股收益 9.000。</p>
</div><h2>Humana Announces Dividend</h2>
<div class="lb-trans"><h2>Humana 宣布分红</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Friday, June 26th. Humana's dividend payout ratio (DPR) is currently 37.86%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 7 月 31 日星期五支付。6 月 26 日星期五的股东将获得每股 0.885 美元的分红。这相当于年化分红为 3.54 美元，分红收益率为 1.2%。除息日为 6 月 26 日星期五。Humana 的分红支付比率（DPR）目前为 37.86%。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other Humana news, insider Sanjay K. Shetty bought 810 shares of the company's stock in a transaction that occurred on Monday, February 23rd. The shares were purchased at an average cost of $185.21 per share, for a total transaction of $150,020.10. Following the purchase, the insider directly owned 11,657 shares in the company, valued at $2,158,992.97. This represents a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.20% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 Humana 新闻中，内部人士 Sanjay K. Shetty 在 2 月 23 日星期一购买了 810 股该公司的股票。每股的平均购买成本为 185.21 美元，总交易额为 150,020.10 美元。购买后，该内部人士直接持有该公司 11,657 股股票，价值为 2,158,992.97 美元。这代表了他们持股比例的 7.47% 的增长。该收购已在与 SEC 的法律文件中披露，可以通过此超链接访问。当前，内部人士持有该股票的 0.20%。</p>
</div><h2>Institutional Investors Weigh In On Humana</h2>
<div class="lb-trans"><h2>机构投资者对 Humana 的看法</h2>
</div><p>Several institutional investors have recently added to or reduced their stakes in HUM. Capital International Investors increased its holdings in shares of Humana by 113.9% during the fourth quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider's stock valued at $1,490,239,000 after acquiring an additional 3,097,571 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Humana by 273.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,488,261 shares of the insurance provider's stock worth $907,541,000 after purchasing an additional 2,553,509 shares in the last quarter. Norges Bank purchased a new stake in Humana during the 4th quarter worth approximately $456,632,000. Pzena Investment Management LLC increased its stake in Humana by 34.3% during the 1st quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider's stock valued at $948,614,000 after purchasing an additional 1,398,774 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in Humana by 4,481.7% during the 4th quarter. Wellington Management Group LLP now owns 1,196,502 shares of the insurance provider's stock valued at $306,460,000 after purchasing an additional 1,170,387 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近增加或减少了对 HUM 的持股。资本国际投资者在第四季度将其在 Humana 的持股增加了 113.9%。资本国际投资者现在拥有 5,818,008 股该保险提供商的股票，价值为 14.90239 亿美元，此前在上个季度又增持了 3,097,571 股。马萨诸塞金融服务公司在第三季度将其在 Humana 的持股增加了 273.2%。马萨诸塞金融服务公司现在拥有 3,488,261 股该保险提供商的股票，价值为 9.07541 亿美元，此前在上个季度又增持了 2,553,509 股。挪威银行在第四季度购买了 Humana 的新股份，价值约为 4.56632 亿美元。Pzena 投资管理公司在第一季度将其在 Humana 的持股增加了 34.3%。Pzena 投资管理公司现在拥有 5,470,982 股该保险提供商的股票，价值为 9.48614 亿美元，此前在上个季度又增持了 1,398,774 股。最后，威灵顿管理集团在第四季度将其在 Humana 的持股增加了 4,481.7%。威灵顿管理集团现在拥有 1,196,502 股该保险提供商的股票，价值为 3.06460 亿美元，此前在上个季度又增持了 1,170,387 股。机构投资者和对冲基金持有该公司 92.38% 的股票。</p>
</div><h2>Humana Company Profile</h2>
<div class="lb-trans"><h2>Humana 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.</p>
<div class="lb-trans"><p>Humana Inc（纽约证券交易所代码：HUM）是一家总部位于肯塔基州路易斯维尔的健康保险公司，主要为美国各地的个人和团体提供服务。该公司以其医疗保险业务而闻名，提供医疗保险优势计划和处方药（D 部分）覆盖，同时还提供一系列商业和雇主赞助的团体健康计划。Humana 的产品旨在满足会员的医疗、行为健康和药房需求，特别强调老年人和符合医疗保险资格的人群。</p>
</div><p>In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.</p>
<div class="lb-trans"><p>除了传统的保险产品外，Humana 还提供旨在支持慢性病管理、预防护理和护理协调的护理管理和健康服务。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Humana</li>
<li>Airplane Maintenance Companies That Keep Flights Moving Are Ready to Soar</li>
<li>Oklo Stock Could Be Ready for Another Massive Run</li>
<li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li>
<li>Nebius Upside Expands as AI Feedback Loop Intensifies</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Humana</li>
<li>保持航班正常的飞机维修公司准备腾飞</li>
<li>Oklo 股票可能准备再次大幅上涨</li>
<li>D-Wave 的财报看起来疲弱，但投资者可能忽视了这一点</li>
<li>随着人工智能反馈循环的加剧，Nebius 的上行空间扩大</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhVTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=HUM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Humana Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Humana 吗？</h2>
</div><p>Before you consider Humana, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Humana 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Humana 并不在名单上。</p>
</div><p>While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Humana 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Zacks 研究公司对休曼纳的盈利前景发布了负面展望